본문 바로가기
KERD
논문KCI 등재

Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials

Archana Mishra|Rituparna Maiti|Biswa Ranjan Mishra|Anand Srinivasan
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2024.05|Clinical Psychopharmacology and Neuroscience|제22권 제2호|pp. 232-252|DOI 10.9758/cpn.23.1119

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

SchizophreniaClozapineClozapine-resistantAugmentation therapy

초록

Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/non-responders to clozapine. Relevant data were extracted from 30 randomized controlled trials through searches of electronic databases (MEDLINE/PubMed, Embase, Cochrane, clinical trial registries). PRISMA guidelines were followed for the extraction, management, analysis, and reporting of the data. The outcome measure in this study was a reduction in symptom severity according to total PANSS/BPRS and was reported as the standardized mean difference with a 95% credible interval. Bayesian network meta-analysis with random effects model and uninformative priors was conducted, and the ranking probability of each intervention was done. Meta-regression was done to assess the effect of duration on the reduction in symptom severity scores. Mirtazapine (−5.2 [95%CrI: −7.7, −2.7]) and memantine (−2.1 [95%CrI: −4.0, −0.19]) were more efficacious than placebo for augmentation of clozapine in partial/non-responders and were the most effective adjunctive agents as per SUCRA scores. Both drugs did not cause a significant increase in frequency of adverse events compared to placebo. There was a significant effect of duration on the reduction in symptom severity. There was no evident publication bias. Mirtazapine and memantine may prove beneficial for augmentation of clozapine in non/partial responders to monotherapy.

Abstract

Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/non-responders to clozapine. Relevant data were extracted from 30 randomized controlled trials through searches of electronic databases (MEDLINE/PubMed, Embase, Cochrane, clinical trial registries). PRISMA guidelines were followed for the extraction, management, analysis, and reporting of the data. The outcome measure in this study was a reduction in symptom severity according to total PANSS/BPRS and was reported as the standardized mean difference with a 95% credible interval. Bayesian network meta-analysis with random effects model and uninformative priors was conducted, and the ranking probability of each intervention was done. Meta-regression was done to assess the effect of duration on the reduction in symptom severity scores. Mirtazapine (−5.2 [95%CrI: −7.7, −2.7]) and memantine (−2.1 [95%CrI: −4.0, −0.19]) were more efficacious than placebo for augmentation of clozapine in partial/non-responders and were the most effective adjunctive agents as per SUCRA scores. Both drugs did not cause a significant increase in frequency of adverse events compared to placebo. There was a significant effect of duration on the reduction in symptom severity. There was no evident publication bias. Mirtazapine and memantine may prove beneficial for augmentation of clozapine in non/partial responders to monotherapy.

참고문헌 (59)

  1. Lao KSJ, "Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014 : general and vulnerable patient groups", Pharmacoepidemiol Drug Saf, 26, pp.1387~1394 (2017)
  2. Kane JM, "The role of clozapine in treatment-resistant schizophrenia", JAMA Psychiatry, 73, pp.187~188 (2016)
  3. Lieberman JA, "Clinical effects of clozapine in chronic schizophrenia : response to treatment and predictors of outcome", Am J Psychiatry, 151, pp.1744~1752 (1994)
  4. Meltzer HY, "Treatment-resistant schizophrenia--the role of clozapine", Curr Med Res Opin, 14, pp.1~20 (1997)
  5. Kapur S, "Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia", Am J Psychiatry, 156, pp.286~293 (1999)
  6. Davis J, "Neuroprogression in schizophrenia : pathways underpinning clinical staging and therapeutic corollaries", Aust N Z J Psychiatry, 48, pp.512~529 (2014)
  7. Sernyak MJ, "Clinicians’ reasons for antipsychotic coprescribing", J Clin Psychiatry, 65, pp.1597~1600 (2004)
  8. Moher D, "Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P)2015 statement", Syst Rev, 4, pp.1~ (2015)
  9. Hutton B, "The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions : checklist and explanations", Ann Intern Med, 162, pp.777~784 (2015)
  10. "PlotDigitizer"[URL]
  11. "Gemtc: network meta-analysis using bayesian methods"[URL]
  12. Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
  13. Anil Yağcioğlu AE, "A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine : efficacy and safety", J Clin Psychiatry, 66, pp.63~72 (2005)
  14. Assion HJ, "Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial", Pharmacopsychiatry, 41, pp.24~28 (2008)
  15. Barbui C, "Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care : A randomized, controlled trial", J Clin Psychopharmacol, 31, pp.266~273 (2011)
  16. Barnes TR, "Amisulpride augmentation in clozapine-unresponsive schizophrenia(AMICUS) : a double-blind, placebo-controlled, randomised trial of clinical effectiveness and costeffectiveness", Health Technol Assess, 21, pp.1~56 (2017)
  17. Chang JS, "Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia : an 8-week, randomized, doubleblind, placebo-controlled trial", J Clin Psychiatry, 69, pp.720~731 (2008)
  18. de Lucena D, "Improvement of negative and positive symptoms in treatment-refractory schizophrenia : a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine", J Clin Psychiatry, 70, pp.1416~1423 (2009)
  19. Doruk A, "A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia", Int Clin Psychopharmacol, 23, pp.223~227 (2008)
  20. Freudenreich O, "Risperidone augmentation for schizophrenia partially responsive to clozapine : a double-blind, placebo-controlled trial", Schizophr Res, 92, pp.90~94 (2007)
  21. Friedman JI, "Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy", Neuropsychopharmacology, 36, pp.1289~1295 (2011)
  22. Genç Y, "Comparison of clozapineamisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine : a single-blind randomized study", Adv Ther, 24, pp.1~13 (2007)
  23. Gunduz-Bruce H, "Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia", Schizophr Res, 143, pp.344~347 (2013)
  24. Honer WG, "Clozapine alone versus clozapine and risperidone with refractory schizophrenia", N Engl J Med, 354, pp.472~482 (2006)
  25. Josiassen RC, "Clozapine augmented with risperidone in the treatment of schizophrenia : a randomized, double-blind, placebo-controlled trial", Am J Psychiatry, 162, pp.130~136 (2005)
  26. Kelly DL, "Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms", J Clin Psychopharmacol, 35, pp.374~381 (2015)
  27. Lane HY, "Glycine transporter I inhibitor, N-methylglycine(sarcosine), added to clozapine for the treatment of schizophrenia", Biol Psychiatry, 60, pp.645~649 (2006)
  28. Lin CH, "Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia : a randomized, double-blind, placebo-controlled trial", Biol Psychiatry, 84, pp.422~432 (2018)
  29. Lu ML, "Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia : a 12-week, randomized, double-blind, placebo-controlled study", Schizophr Res, 193, pp.126~133 (2018)
  30. Mico’ U, "Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia : a randomized, placebo-controlled trial", Int Clin Psychopharmacol, 26, pp.303~310 (2011)
  31. Muscatello MR, "Topiramate augmentation of clozapine in schizophrenia : a double-blind, placebo-controlled study", J Psychopharmacol, 25, pp.667~674 (2011)
  32. Muscatello MR, "Effect of aripiprazole augmentation of clozapine in schizophrenia : a double-blind, placebo-controlled study", Schizophr Res, 127, pp.93~99 (2011)
  33. Muscatello MR, "Augmentation of clozapine with ziprasidone in refractory schizophrenia : a double-blind, placebo-controlled study", J Clin Psychopharmacol, 34, pp.129~133 (2014)
  34. Shiloh R, "Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A doubleblind, placebo-controlled study", Br J Psychiatry, 171, pp.569~573 (1997)
  35. Tiihonen J, "Lamotrigine in treatment-resistant schizophrenia : a randomized placebo-controlled crossover trial", Biol Psychiatry, 54, pp.1241~1248 (2003)
  36. Vayısoğlu S, "Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment", Schizophr Res, 143, pp.207~214 (2013)
  37. Weiner E, "Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine", Neuropsychopharmacology, 35, pp.2274~2283 (2010)
  38. Zhu MH, "Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia : a 12-week randomized, double-blind, placebo-controlled trial", Mil Med Res, 9, pp.59~ (2022)
  39. Zink M, "Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine : a randomised controlled clinical trial", J Psychopharmacol, 23, pp.305~314 (2009)
  40. Zoccali R, "The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia : a double-blind, placebo-controlled study", Int Clin Psychopharmacol, 19, pp.71~76 (2004)
  41. Zoccali R, "The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients : a double-blind, placebo-controlled study", Schizophr Res, 93, pp.109~116 (2007)
  42. Evins AE, "Placebocontrolled trial of glycine added to clozapine in schizophrenia", Am J Psychiatry, 157, pp.826~828 (2000)
  43. Nielsen J, "Augmenting clozapine with sertindole : a doubleblind, randomized, placebo-controlled study", J Clin Psychopharmacol, 32, pp.173~178 (2012)
  44. Buchanan RW, "Fluoxetine augmentation of clozapine treatment in patients with schizophrenia", Am J Psychiatry, 153, pp.1625~1627 (1996)
  45. Fleischhacker WW, "Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine : a randomized, double-blind, placebo-controlled trial", Int J Neuropsychopharmacol, 13, pp.1115~1125 (2010)
  46. Tsai GE, "D-serine added to clozapine for the treatment of schizophrenia", Am J Psychiatry, 156, pp.1822~1825 (1999)
  47. Goff DC, "A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia", Biol Psychiatry, 45, pp.512~514 (1999)
  48. Goff DC, "A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia", J Clin Psychopharmacol, 21, pp.484~487 (2001)
  49. Gray L, "Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse : association with N-methyl-D-aspartic acid receptor up-regulation", Int J Neuropsychopharmacol, 12, pp.45~60 (2009)
  50. Lieberman JA, "A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia", Neuropsychopharmacology, 34, pp.1322~1329 (2009)
  51. Montgomery A, "Cariprazine-an alternative treatment for clozapine-resistant schizophrenia?", Clin Psychopharmacol Neurosci, 21, pp.202~206 (2023)
  52. Correll CU, "Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia : systematic overview and quality appraisal of the meta-analytic evidence", JAMA Psychiatry, 74, pp.675~684 (2017)
  53. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophrenia : systematic review, meta-analysis and meta-regression analysis", World Psychiatry, 16, pp.77~89 (2017)
  54. Nucifora FC Jr, "Treatment resistant schizophrenia : clinical, biological, and therapeutic perspectives", Neurobiol Dis, 131, pp.104257~ (2019)
  55. Yeh TC, "Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia : a systematic review and network meta-analysis with normalized entropy assessment", Asian J Psychiatr, 79, pp.103375~ (2023)
  56. Campana M, "Characteristics and definitions of ultra-treatment-resistant schizophrenia-A systematic review and meta-analysis", Schizophr Res, 228, pp.218~226 (2021)
  57. Tiihonen J, "The efficacy of lamotrigine in clozapine-resistant schizophrenia : a systematic review and meta-analysis", Schizophr Res, 109, pp.10~14 (2009)
  58. Siskind DJ, "Augmentation strategies for clozapine refractory schizophrenia : a systematic review and meta-analysis", Aust N Z J Psychiatry, 52, pp.751~767 (2018)
  59. Bighelli I, "Are randomized controlled trials on pharmacotherapy and psychotherapy for positive symptoms of schizophrenia comparable? A systematic review of patient and study characteristics", Schizophr Bull, 46, pp.496~504 (2020)

관련 논문AI추천

Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase SchizophreniaHiroto Ito, Kotaro Hatta대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2014 · 제12권 제1호Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study박원명, Bo-Hyun Yoon, Sheng Min Wang, Sung-Yong Park, Won-Seok Choi, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2022 · 제20권 제3호The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial김보라, 이상혁, 최아영, Jieun Lee, Kang Soo Lee, Keung-Hyang Kim, Keunyoung Yook, Sungjae Lee, Sung Joon Cho, Tae Kyou Choi대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2011 · 제9권 제2호Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study박영민, 박원명, 박주언, 우영섭, 정종현, Do-Hoon Kim, Duk-In Jon, Inki Sohn, Tae Yeon Hwang대한신경정신의학회 · PSYCHIATRY INVESTIGATION2016 · 제13권 제4호조현병 스펙트럼 장애의 1년 유지 치료에서 클로자핀과 병용 치료제의 처방 양상 분석강태욱, 권준수, 김민아, 김세현, 김재원, 문선영, 장진혁대한생물정신의학회 · 생물정신의학2021 · 제28권 제2호Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia윤탁, 김세현, 김용식, 김혜성, 이남영, 이정혁, 정승현, 정인원대한신경정신의학회 · PSYCHIATRY INVESTIGATION2017 · 제14권 제1호

이 간행물의 다른 논문 (19건)

A Critical View on New and Future AntidepressantsAlessandro Serrettipp. 201-210Bipolar Disorder, Circadian Rhythm and Clock GenesYoung-Chan Kim, Junsoo Chung, 정종현pp. 211-221Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical TrialsHyun Kook Lim, 배치운, 김성환, Young Sup Woo, Sheng-Min Wang, Won-Myong Bahk, Won-Seok Choipp. 222-231Effect of Frailty on Depression among Patients with Late-life Depression: A Test of Anger, Anxiety, and Resilience as MediatorsHyun-Ghang Jeong, 이문수, 배치운, Changsu Han, Junhyung Kim, Ashwin A. Patkar, Cheolmin Shin, Sang Won Jeonpp. 253-262The Dropout Rates and Associated Factors in Patients with Mood Disorders in Long-term Naturalistic TreatmentHee Jeong Jeong, Je Min Park, Wooyoung Jung, Byung Dae Lee, Young Min Lee, Hwagyu Suh, Hyun Ju Lim, Eunsoo Moon, Kyungwon Kimpp. 263-275
원문 보기